In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

This content is currently on FREE ACCESS

Learnings from the latest PCSK9i results and profiles of patients who may benefit the most: a comprehensive review of the latest lipid lowering therapies outcomes data

Session Identifying patients who may benefit most from PCSK9i: highlights from the latest ODYSSEY OUTCOMES data

Speaker Christopher Paul Cannon

Event : ESC Congress 2018

  • Topic : preventive cardiology
  • Sub-topic : Lipids
  • Session type : Satellite Symposium
  • Sponsored by Sanofi and Regeneron

This content is currently on FREE ACCESS

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are